Staccato Alprazolam in Panic Attack
Investigation of a Single Dose of Staccato™ Alprazolam for Inhalation on Doxapram-Induced Panic Attack in Patients With Panic Disorder
Sponsor: Alexza Pharmaceuticals, Inc.
A PHASE2 clinical study on Treatment of Induced Panic Attack, this trial is completed. The trial is conducted by Alexza Pharmaceuticals, Inc. and has accumulated 10 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2026 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alexza Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .